Biotech entity
Against the same-window beat baseline of 20% negative, this entity's 83% share is more negative. Bundibugyo ebolavirus is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. clinical-trial accounts for 4 of the 6 tracked stories, while 1 other category carries the remainder.
Last mentioned: Aug 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 83 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Against the same-window beat baseline of 20% negative, this entity's 83% share is more negative. Bundibugyo ebolavirus is the most frequent co-covered peer, appearing in 3 of the 6 tracked stories. clinical-trial accounts for 4 of the 6 tracked stories, while 1 other category carries the remainder. Source depth averages 3 original sources per story, versus 3.8 across the same-window beat baseline. Across a 66-day span, the pace is roughly 0.6 stories per week. The 6.8 average consequence score is above the beat benchmark of 6.1 in the same window. Ituri province appears in 6 tracked Biotech stories published from June 15, 2026 through August 19, 2026.
Computed from the 6 stories linked to this entity, with beat comparisons drawn from all 280 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ituri province. Shared-story counts are live from our verified record — not editorial picks.
Leadership Visits and Latest Data Released
Africa CDC Director-General Jean Kaseya visited Bunia, WHO Director-General Tedros arrived in Kinshasa; government update reported 3,802 cases and 1,707 deaths.
Healthcare Workers Issue Ultimatum
In Mongbwalu, healthcare workers threatened to escalate action within 24 hours if unpaid wages were not resolved.
3,000 Cases Milestone
Total cases reach 3,075, with 1,354 deaths, amid healthcare strikes and calls for accelerated countermeasure development.
First Experimental Vaccine Volunteer Dosed
Oxford University reports that the first volunteer group has received its candidate vaccine specifically targeting Bundibugyo.
2,000 Cases Surpassed
Cumulative confirmed cases exceed 2,000, with rapid spread noted in conflict zones.
Staff strike at Rwampara General Hospital
Dozens of workers at the epicenter treatment center strike over two months of unpaid salaries, shutting the facility and blocking roads.
Virus spreads to two more provinces
Health Minister Kamba announces the outbreak has reached two additional provinces beyond Ituri, further complicating containment.
Experimental treatment study begins
A clinical study of two candidate Ebola treatments launches at a different treatment center in Ituri province, not the one that would later strike.
Uganda Declared Ebola‑Free
Neighboring Uganda discharged its last Ebola patient, ending its own transmission chain linked to the Congo outbreak.
Outbreak Declared
DR Congo announces its 17th Ebola outbreak, identifying the Bundibugyo strain as the cause.
Official outbreak declaration
Congolese authorities declare a Bundibugyo Ebola outbreak after weeks of undetected transmission due to initial misdiagnosis.
The current Ebola outbreak in eastern Congo is caused by Bundibugyo virus, a less common species with no approved treatment or vaccine. With 5,000+ cases and 2,300+ deaths, it reveals a critical gap in filovirus countermeasure development and rapid-response platforms.
Source: abcnews.com · krmg.com
Congo’s Bundibugyo Ebola outbreak has surged to 3,802 cases and 1,707 deaths, highlighting an urgent need for vaccines and treatments. With no approved products available, two post‑exposure prophylaxis trials in Ituri and two vaccine trials in the UK and Canada are now underway, while nearly 80% of new cases elude contact tracing.
Source: wfmj.com · orlandosentinel.com
Biotech's race to develop therapies for the Bundibugyo Ebola strain faces a new hurdle as a strike at Congo's outbreak epicenter disrupts critical clinical operations. The study of two candidate treatments, launched in early July, could be jeopardized by collapsed workforce morale at nearby facilities.
Source: mcall.com
DRC’s 17th Ebola outbreak has exploded to 3,075 cases and 1,354 deaths, with 1,000 new infections in just 10 days. The Bundibugyo strain has no approved vaccine or treatment, igniting a biotech race: Oxford University has dosed its first volunteer with an experimental vaccine, while other candidates are fast-tracked, creating high-stakes opportunities for pharma developers.
Source: english.aawsat.com · manilatimes.net
The fastest-growing Ebola outbreak in history is driven by the Bundibugyo virus, which lacks any approved vaccine or therapy. With over 2,100 cases and 864 deaths, biopharma companies face a pressing unmet need and a potential market for rapid filovirus countermeasure development.
Source: wral.com · breitbart.com
The rare Bundibugyo Ebola virus has infected 782 people and killed 181 in Congo, with a record 72 new cases in one day. No approved vaccine or treatment exists for this strain, creating an urgent gap for biotech and pharma to address with rapid countermeasure development.
Ituri province is linked from 6 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
